Submissions received during the consultation on the Guideline Monitoring and Evaluation Plan

  1. AbbVie Corporation (PDF 226 KB)
  2. Amgen Canada Inc. (PDF 393 KB)
  3. Arthritis Society (PDF 139 KB)
  4. Astellas Pharma Canada Inc. (PDF 638 KB)
  5. Bayer Inc. (PDF 206 KB)
  6. Best Medicines Coalition (PDF 243 KB)
  7. Biogen Canada (PDF 167 KB)
  8. BIOQuébec [in French only] (PDF 203 KB)
  9. BIOTECanada (PDF 151 KB)
  10. Boehringer Ingelheim (Canada) Ltd (PDF 192 KB)
  11. Canadian Health Research Forum (PDF 449 KB)
  12. Canadian Life and Health Insurance Association (CLHIA) (PDF 624 KB)
  13. Canadian Organization for Rare Disorders (CORD) (PDF 141 KB)
  14. Council of Senior Citizens' Organization of BC  (PDF 169 KB)
  15. Cystic Fibrosis Canada (PDF 260 KB)
  16. Elvium Life Sciences (PDF 111 KB)
  17. Gastrointestinal Society (PDF 197 KB)
  18. Innovative Medicines Canada (PDF 135 KB)
  19. Janssen Inc (PDF 134 KB)
  20. Life Sciences BC  (PDF 217 KB)
  21. Life Sciences Ontario (PDF 202 KB)
  22. McKesson Canada Corporation (PDF 548 KB)
  23. Medicines Access Coalition  BC (PDF 839 KB)
  24. Merck Canada Inc. (PDF 178 KB)
  25. Multiple Sclerosis Society of Canada (PDF 245 KB)
  26. Novartis Pharma Canada Inc (PDF 423 KB)
  27. Pfizer Canada ULC (PDF 115 KB)
  28. Protect our Access (umbrella group for 15 patient groups) (PDF 155 KB)
  29. Sanofi Canada (PDF 139 KB)
  30. Save Your Skin Foundation (PDF 483 KB)
  31. Servier Canada Inc. (PDF 196 KB)
  32. Sunovion Pharmaceuticals Canada Inc. (PDF 192 KB)
  33. Takeda Canada (PDF 145 KB)
  34. The Canadian Association for Pharmacy Distribution Management (CAPDM) (PDF 242 KB)
  35. The Canadian Forum for Rare Innovators (RAREi) (PDF 218 KB)
  36. The Neighbourhood Pharmacy Association of Canada (PDF 160 KB)
  37. Vaccine Industry Committee (PDF 96 KB)
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: